The other 5% of the adult pneumoccal-vaccine market is MRK's offering: Vaxneuvance (a/k/a V114) followed by MRK's 1980s product, Pneumovax (#msg-166441188). The need for two injections and two appointments is why MRK has only a 5% market share.
MRK has a newer vaccine, V116, which is not yet on the market but is slated to be a serious competitor to Prevnar-20 in the adult market (#msg-172452293).
News 
Market Data 
Discover 
